CDK4/6 inhibitor PD 0332991 sensitizes acute myeloid leukemia to cytarabine-mediated cytotoxicity Journal Article


Authors: Yang, C. Y.; Boyson, C. A.; Di Liberto, M.; Huang, X. G.; Hannah, J.; Dorn, D. C.; Moore, M. A. S.; Chen-Kiang, S.; Zhou, P. B.
Article Title: CDK4/6 inhibitor PD 0332991 sensitizes acute myeloid leukemia to cytarabine-mediated cytotoxicity
Abstract: Cyclin-dependent kinase (CDK) 4 and CDK6 are frequently overexpressed or hyperactivated in human cancers. Targeting CDK4/CDK6 in combination with cytotoxic killing therefore represents a rational approach to cancer therapy. By selective inhibition of CDK4/CDK6 with PD 0332991, which leads to early G(1) arrest and synchronous S-phase entry upon release of the G(1) block, we have developed a novel strategy to prime acute myeloid leukemia (AML) cells for cytotoxic killing by cytarabine (Ara-C). This sensitization is achieved in part through enrichment of S-phase cells, which maximizes the AML populations for Ara-C incorporation into replicating DNA to elicit DNA damage. Moreover, PD 0332991 triggered apoptosis of AML cells through inhibition of the homeobox (HOX) A9 oncogene expression, reducing the transcription of its target PIM1. Reduced PIM1 synthesis attenuates PIM1-mediated phosphorylation of the proapoptotic BAD and activates BAD-dependent apoptosis. In vivo, timely inhibition of CDK4/CDK6 by PD 0332991 and release profoundly suppresses tumor growth in response to reduced doses of Ara-C in a xenograft AML model. Collectively, these data suggest selective and reversible inhibition of CDK4/CDK6 as an effective means to enhance Ara-C killing of AML cells at reduced doses, which has implications for the treatment of elderly AML patients who are unable to tolerate high-dose Ara-C therapy. (C) 2015 AACR.
Keywords: gene; mantle cell lymphoma; degradation; expansion; kinases; hoxa9; bone-marrow-cells; pharmacological inhibition; cancer; early g(1) arrest
Journal Title: Cancer Research
Volume: 75
Issue: 9
ISSN: 0008-5472
Publisher: American Association for Cancer Research  
Date Published: 2015-05-01
Start Page: 1838
End Page: 1845
Language: English
ACCESSION: WOS:000353706600007
DOI: 10.1158/0008-5472.can-14-2486
PROVIDER: wos
PMCID: PMC4417369
PUBMED: 25744718
Notes: Article -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. David Christian Dorn
    13 Dorn
  2. Malcolm A S Moore
    549 Moore